Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21
±³À°ÀÏÀÚ : 2024-06-21
±³À°Àå¼Ò : ¼¿ï·Ôµ¥È£ÅÚ
±³À°ÁÖÁ¦ : Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2
ÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486
À̸ÞÀÏ : cancer2@kams.or.kr
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú, ¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀÎ : 1500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 17 ½Ã°£ 55ºÐ
¼¼ºÎ¼ö°·á : 250,000¿ø
ºñ°í "1. ȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 12¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 7¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 18¸¸¿ø, 2. ºñȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 18¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 7¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 25¸¸¿ø"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 09:00~09:25 Preclinical study of biparatopic ADC targeting MET to overcome acquired resistance to EGFR TKI in EGFR-mutant NSCLC ÀÓ¼±¹Î(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 09:25~09:50 Next-generation antibody ±èÈ£¹Î(KAIST)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 09:50~10:15 Engineering next generation T cell therapy for cancer ±èÂùÇõ(¼¿ï´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 10:15~10:40 The next generation CAR-T therapies landscape ¼Çü¼®(¼¿ï´ë ¾à´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 09:00~09:25 A system development methodology using protein 3D structure prediction in the field of biomedicine È«µ¿¿Ï(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 09:25~09:50 Machine leaning on cancer genome and immune data can predict chemotherapy response of upper GI cancers Hidewaki Nakagawa(RIKEN Center for Integrative Medical Sciences)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 09:50~10:15 AI using multiple clinical & imaging data for cancer research Á¤±Ôȯ(»ï¼ºÀ¶ÇÕÀÇ°úÇпø)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 10:15~10:40 AI development and real-world validation through medical imaging standardization À±¼øÈ£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 09:00~09:25 Evolution of the WHO classifications of CNS tumors in the molecular era ±è¼¼ÈÆ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 09:25~09:50 Lymphoma ÀüÀ±°æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 09:50~10:15 Breast tumors Puay Hoon Tan(Duke-NUS Medical School)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 10:15~10:40 Tumors of the gastrointestinal tracts ±è°æ¹Ì(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 09:00~09:20 A first-line treatment option for locally advanced unresectable or metastatic biliary track cancer õÀç°æ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 09:20~10:00 A journey to the hope of HR+/HER2- EBC&MBC patient: Abemaciclib new data ÀÌÁöÀº(°¡Å縯ÀÇ´ë)
ÈÞ½Ä 06¿ù 21ÀÏ 10:40~11:00 ÈÞ½Ä ()
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 11:00~11:40 Evolution of cancer treatment and development of Korean Cancer Association ¹æ¿µÁÖ(¼¿ïÀÇ´ë/¹æ¾Ø¿Á)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 11:40~12:20 How whole genome sequencing can advance precision medicine Emile Voest(Netherlands Cancer Institute)
ÈÞ½Ä 06¿ù 21ÀÏ 12:20~12:30 ÈÞ½Ä ()
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 12:30~13:10 Unlocking the door: A paradigm shift in early-stage NSCLC treatment with pembrolizumab À̼¼ÈÆ(¼º±Õ°üÀÇ´ë)
ÈÞ½Ä 06¿ù 21ÀÏ 13:10~14:30 ÈÞ½Ä ()
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 14:30~14:55 Whole-genome sequencing reveals the homologous recombination deficiency in human cancer ÁÖ¿µ¼®(KAIST)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 14:55~15:20 Metabolic triggers for cancer genome evolution Ashok Venkitaraman(National University of Singapore)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 15:20~15:45 In vivo CRISPR therapy targeting cancer-specific genetic alterations ±ÇÅÂÁØ(UNIST)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 15:45~16:10 Targeting DNA damage repair deficiency in gynaecological cancers David SP Tan(National University Cancer Institute)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 14:30~14:55 Role of vascular functions in cancer treatment ¼Ûâ¿ø(University of Minnesota)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 14:55~15:20 Vascular regulation of tumor immune exclusion and progression ±è¹Î¾Æ(Columbia University Medical Center)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 15:20~15:45 Hypoxia as a regulator of tumor stroma ÀÌ°æÀº(University of Michigan)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 14:30~14:55 Proteogenomic characterization reveals estrogen signaling as a target for never-smoker lung adenocarcinoma patients without EGFR or ALK alterations ±è¼±¿µ(Çѱ¹»ý¸í°øÇבּ¸¿ø)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 14:55~15:20 Emerging therapeutic targets for systemic treatment of advanced gastric cancer ±èÀÎÈ£(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 15:20~15:45 Single cell-based target identification in cancers ¹ÚÁöȯ(GIST)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 15:45~16:10 Dissecting heterogeneity of histologic patterns reveals a novel target of lung adenocarcinoma À̽ſ±(°æºÏÀÇ´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 14:30~14:55 Pathology insights in MDT: Driving precision diagnostics and treatment in cancer care ÀÌÇý½Â(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 14:55~15:20 The vital importance of the multidisciplinary team win managing lung cancer: A thoracic surgeon¡¯s view ÀÌ⿵(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 15:20~15:45 Navigating the cancer journey: The integral role of medical oncology in MDT strategies ¹Ú¼¼ÈÆ(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 15:45~16:10 Targeting cancer with precision: The integral role of radiation oncology in MDT strategies À̼º¿í(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 14:30~14:45 ±¹°¡ ¾ÏÁø·á°¡À̵å¶óÀÎ »ç¾÷ ÃßÁø ÇöȲ °ûÈ£½Å(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 14:45~15:00 ¾ÏÁø·á°¡À̵å¶óÀÎ °³¹ß ¹æ¹ý·Ð°ú °Ë¼ö»çÇ× ±è¼ö¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 15:00~15:15 À§¾Ï Áø·á °¡À̵å¶óÀÎ ¼Ò°³ ÇÑÇý¼÷(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 15:15~15:30 °©»ó¼±¾Ï Áø·á °¡À̵å¶óÀÎ ¼Ò°³ ÀÌÀº°æ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 15:30~15:45 °áÀå¾Ï Áø·á °¡À̵å¶óÀÎ ¼Ò°³ °ûÁ¤¸é(°í·ÁÀÇ´ë)
Åä·Ð 06¿ù 21ÀÏ Belle-Vue 15:45~16:10 ÆгÎÅä·Ð ()
ÈÞ½Ä 06¿ù 21ÀÏ 16:10~16:30 ÈÞ½Ä ()
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 16:30~16:50 Tumor informed vs. tumor agnostic ctDNA analysis À̽ÂÅÂ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 16:50~17:10 A new era of molecular residual disease: Optimizing perioperative chemotherapy for colorectal cancer Eiji Oki (Graduate School of Medical Sciences, Kyushu University)
±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 17:10~17:30 ctDNA monitoring in metastatic cancer ÃÖ¿ø¿µ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 16:30~16:50 Mechanisms of oncogenic tyrosine kinase fusion selection in human cancer Á¤ÅÃÁø(Boston Children)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 16:50~17:10 A study on the immunological microenvironment of pancreatic cancer ±è´ö±â(Ãæ³²´ëº´¿ø)
±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 17:10~17:30 Immunotherapy in pancreatic cancer: DNA damage repair deficiency & what else ¹Ú¿õ±â(Memorial Sloan Kettering Cancer Center)